Nastech/Amylin’s Exenatide Nasal Spray Deal Could Be Shot In The Arm For Lilly
This article was originally published in The Pink Sheet Daily
Executive Summary
Lilly, which markets injectable exenatide, may inherit commercialization rights to the nasal spray formulation if Nastech/Amylin’s development proves successful.